{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:40:01Z","timestamp":1756291201459,"version":"3.44.0"},"reference-count":40,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>Varicella-zoster virus (VZV) causes both varicella and herpes zoster.1,2 In 1995 a varicella vaccine was licensed in the USA and was incorporated into the routine vaccination programme for children; a decline of varicella among children and adults, and a reduction in associated hospitalisation, complications and mortality, has resulted.2 In the UK, a policy of targeted vaccination of at-risk groups has been in place since the vaccine was introduced.3 Here we review the evidence for the different approaches to VZV vaccination policy.<\/jats:p>","DOI":"10.1136\/dtb.2012.04.0098","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T06:12:51Z","timestamp":1334124771000},"page":"42-45","source":"Crossref","is-referenced-by-count":3,"title":["Routine vaccination against chickenpox?"],"prefix":"10.1136","volume":"50","member":"239","published-online":{"date-parts":[[2012,4,11]]},"reference":[{"key":"2025082703094280000_50.4.42.1","unstructured":"Salisbury DM . Immunisation against infectious disease. Third edition. London: TSO, 2006 [online]. Available: http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_079917 [Accessed 21 March 2012]."},{"issue":"(RR-4)","key":"2025082703094280000_50.4.42.2","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"2025082703094280000_50.4.42.3","unstructured":"Department of Health, 2010. Joint Committee on Vaccination and Immunisation statement on varicella and herpes zoster vaccines [online]. Available: http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/@dh\/@ab\/documents\/digitalasset\/dh_114908.pdf [Accessed 21 March 2012]."},{"key":"2025082703094280000_50.4.42.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70313-5"},{"key":"2025082703094280000_50.4.42.5","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2005.43969"},{"key":"2025082703094280000_50.4.42.6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0950268800001278","article-title":"An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987\u201392","volume":"117","author":"Wreghitt","year":"1996","journal-title":"Epidemiol Infect"},{"key":"2025082703094280000_50.4.42.7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7883\/yoken.JJID.2000.47","article-title":"Development of a live varicella vaccine\u2013past and future","volume":"53","author":"Takahashi","year":"2000","journal-title":"Jpn J Infect Dis"},{"key":"2025082703094280000_50.4.42.8","unstructured":"Varilrix. Summary of product characteristics, UK. GSK, January 2012."},{"key":"2025082703094280000_50.4.42.9","unstructured":"\u25bcVarivax. Summary of product characteristics, UK. Sanofi Pasteur\/MSD, June 2011."},{"key":"2025082703094280000_50.4.42.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405313102201"},{"key":"2025082703094280000_50.4.42.11","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90189-D"},{"key":"2025082703094280000_50.4.42.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.Supplement_3.S330"},{"key":"2025082703094280000_50.4.42.13","first-page":"604","article-title":"Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"2025082703094280000_50.4.42.14","first-page":"748","article-title":"Varicella vaccine studies in healthy children and adults","volume":"78","author":"Arbeter","year":"1986","journal-title":"Pediatrics"},{"key":"2025082703094280000_50.4.42.15","doi-asserted-by":"crossref","unstructured":"Macartney K McIntyre P . Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev 2008; 3: CD001833. DOI: 10.1002\/14651858.CD001833.pub2. [Last assessed as up-to-date: February 2008].","DOI":"10.1002\/14651858.CD001833.pub2"},{"key":"2025082703094280000_50.4.42.16","doi-asserted-by":"publisher","DOI":"10.1086\/522125"},{"key":"2025082703094280000_50.4.42.17","doi-asserted-by":"publisher","DOI":"10.1136\/adc.85.2.83"},{"key":"2025082703094280000_50.4.42.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111283252204"},{"key":"2025082703094280000_50.4.42.19","first-page":"241","article-title":"Varicella vaccines - WHO position paper","volume":"73","author":"World Health Organization","year":"1998","journal-title":"Wkly Epidemiol Rec"},{"key":"2025082703094280000_50.4.42.20","doi-asserted-by":"publisher","DOI":"10.1086\/522156"},{"key":"2025082703094280000_50.4.42.21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0012"},{"key":"2025082703094280000_50.4.42.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.7.797"},{"key":"2025082703094280000_50.4.42.23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200321010-00002","article-title":"Economic evaluations of varicella vaccination programmes: a review of the literature","volume":"21","author":"Thiry","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"2025082703094280000_50.4.42.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00180-9"},{"key":"2025082703094280000_50.4.42.25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.88.10.862"},{"key":"2025082703094280000_50.4.42.26","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880400281X"},{"key":"2025082703094280000_50.4.42.27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-5-68"},{"key":"2025082703094280000_50.4.42.28","doi-asserted-by":"publisher","DOI":"10.1086\/430325"},{"key":"2025082703094280000_50.4.42.29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"(RR-5)","key":"2025082703094280000_50.4.42.30","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2025082703094280000_50.4.42.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-007-0424-0"},{"key":"2025082703094280000_50.4.42.32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.1.136"},{"key":"2025082703094280000_50.4.42.33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"200","journal-title":"JAMA"},{"key":"2025082703094280000_50.4.42.34","first-page":"166","article-title":"Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings","volume":"87","author":"Diaz","year":"1991","journal-title":"Pediatrics"},{"key":"2025082703094280000_50.4.42.35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.Supplement_3.S320"},{"key":"2025082703094280000_50.4.42.36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2005.09.028","article-title":"The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles","volume":"24","author":"Moira","year":"2006","journal-title":"Vaccine"},{"key":"2025082703094280000_50.4.42.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38170.691956.AE"},{"key":"2025082703094280000_50.4.42.38","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.2.214-218.2006"},{"key":"2025082703094280000_50.4.42.39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jinf.2010.06.012","article-title":"Humoral immunity following chickenpox is influenced by geography and ethnicity","volume":"61","author":"Ayres","year":"2010","journal-title":"J Infect"},{"key":"2025082703094280000_50.4.42.40","doi-asserted-by":"publisher","DOI":"10.1086\/501900"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2012.04.0098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:09:56Z","timestamp":1756289396000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2012.04.0098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,11]]},"published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1136\/dtb.2012.04.0098"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2012.04.0098","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}